Ensign Peak Advisors’s Nurix Therapeutics NRIX Stock Holding History

Ensign Peak Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-230,828	Closed	-$4.38M	–	1725
2025 Q4	$4.38M	Hold	230,828	–	–	0.01%	542
2025 Q3	$2.13M	Hold	230,828	–	–	﹤0.01%	784
2025 Q2	$2.63M	Hold	230,828	–	–	﹤0.01%	818
2025 Q1	$2.74M	Sell	230,828 -143,845	-38%	-$2.41M	0.01%	797
2024 Q4	$7.06M	Buy	374,673 +194,673	+108%	+$4.46M	0.01%	558
2024 Q3	$4.04M	Buy	180,000 +144,356	+405%	+$3.27M	0.01%	701
2024 Q2	$744K	Sell	35,644 -44,263	-55%	-$689K	﹤0.01%	1461
2024 Q1	$1.17M	Hold	79,907	–	–	﹤0.01%	1211
2023 Q4	$825K	Hold	79,907	–	–	﹤0.01%	1486
2023 Q3	$628K	Hold	79,907	–	–	﹤0.01%	1510
2023 Q2	$798K	Hold	79,907	–	–	﹤0.01%	1420
2023 Q1	$710K	Hold	79,907	–	–	﹤0.01%	1505
2022 Q4	$877K	Sell	79,907 -7,060	-8%	-$85.1K	﹤0.01%	1269
2022 Q3	$1.13M	Buy	86,967 +2,170	+3%	+$34.3K	﹤0.01%	1004
2022 Q2	$1.07M	Hold	84,797	–	–	﹤0.01%	1080
2022 Q1	$1.19M	Buy	84,797 +79,907	+1,634%	+$1.42M	﹤0.01%	1103
2021 Q4	$142K	Buy	4,890 +4,091	+512%	+$124K	﹤0.01%	2002
2021 Q3	$24K	Hold	799	–	–	﹤0.01%	1847
2021 Q2	$21K	Hold	799	–	–	﹤0.01%	1819
2021 Q1	$25K	Hold	799	–	–	﹤0.01%	1823
2020 Q4	$26K	Hold	799	–	–	﹤0.01%	1846
2020 Q3	$28K	Buy	+799	New	+$20.1K	﹤0.01%	1735

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Ensign Peak Advisors's NRIX Position: Q1 2026 in Review

Ensign Peak Advisors sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 230,828 shares — an estimated $4.38M sold.

Ensign Peak Advisors first reported a position in NRIX in Q3 2020 and held it in 22 quarters. The position peaked at $7.06M in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Ensign Peak Advisors reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
Ensign Peak Advisors sold 230,828 Nurix Therapeutics shares in Q1 2026, an estimated $4.38M.
Ensign Peak Advisors first reported a position in Nurix Therapeutics in Q3 2020 and held it in 22 quarters.
Ensign Peak Advisors's Nurix Therapeutics position peaked at $7.06M in Q4 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.